Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts
Incidence of CMV and EBV viremia is 51% and 33% in TCR-α/β–depleted transplantation. Neither CMV nor EBV viremia affects survival after TCR-α/β–depleted transplantation. CMV-seronegative donor–CMV-seropositive recipient combination should be avoided. Combined in vivo and ex vivo B cell depletion solves the problem of EBV PTLD. Graft-versus-host disease is associated with increased risk of CMV and EBV viremia.